HB Wealth Management LLC Invests $105,000 in Cardiff Oncology, Inc. (NASDAQ:CRDF)

HB Wealth Management LLC purchased a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 24,500 shares of the company’s stock, valued at approximately $105,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in Cardiff Oncology during the second quarter worth about $27,000. Dimensional Fund Advisors LP grew its position in shares of Cardiff Oncology by 34.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after purchasing an additional 4,892 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Cardiff Oncology during the 3rd quarter worth approximately $64,000. Invst LLC bought a new position in shares of Cardiff Oncology during the second quarter worth approximately $74,000. Finally, American Century Companies Inc. raised its position in shares of Cardiff Oncology by 98.7% in the second quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock valued at $101,000 after buying an additional 22,536 shares in the last quarter. 16.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Piper Sandler upped their target price on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. HC Wainwright cut their price objective on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, November 8th.

Insiders Place Their Bets

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of Cardiff Oncology stock in a transaction that occurred on Wednesday, December 11th. The shares were bought at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the purchase, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. This trade represents a 50.18 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 7.80% of the company’s stock.

Cardiff Oncology Stock Down 2.6 %

Shares of CRDF stock opened at $3.41 on Friday. The business has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $2.90. The company has a market cap of $174.35 million, a P/E ratio of -3.63 and a beta of 1.76. Cardiff Oncology, Inc. has a twelve month low of $1.44 and a twelve month high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. As a group, equities research analysts anticipate that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.